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0022-2836 © 2009 Elsevier Ltd. Open accN-Myristoyltransferase (NMT) catalyses the attachment of the 14-carbon
saturated fatty acid, myristate, to the amino-terminal glycine residue of a
subset of eukaryotic proteins that function in multiple cellular processes,
including vesicular protein trafficking and signal transduction. In these
pathways, N-myristoylation facilitates association of substrate proteins
with membranes or the hydrophobic domains of other partner peptides.
NMT function is essential for viability in all cell types tested to date,
demonstrating that this enzyme has potential as a target for drug
development. Here, we provide genetic evidence that NMT is likely to be
essential for viability in insect stages of the pathogenic protozoan parasite,
Leishmania donovani, causative agent of the tropical infectious disease,
visceral leishmaniasis. The open reading frame of L. donovani NMT has been
amplified and used to overproduce active recombinant enzyme in
Escherichia coli, as demonstrated by gel mobility shift assays of ligand
binding and peptide-myristoylation activity in scintillation proximity
assays. The purified protein has been crystallized in complex with the
non-hydrolysable substrate analogue S-(2-oxo)pentadecyl-CoA, and its
structure was solved by molecular replacement at 1.4 Å resolution. The
structure has as its defining feature a 14-stranded twisted β-sheet on which
helices are packed so as to form an extended and curved substrate-binding
groove running across two protein lobes. The fatty acyl-CoA is largely
buried in the N-terminal lobe, its binding leading to the loosening of a flap,
which in unliganded NMT structures, occludes the protein substrate
binding site in the carboxy-terminal lobe. These studies validate L. donovani
NMT as a potential target for development of new therapeutic agents
against visceral leishmaniasis.© 2009 Elsevier Ltd.Open access under CC BY license. Keywords: N-myristoyltransferase; Leishmania; visceral leishmaniasis;
crystal structure; drug targetEdited by I. Wilsoness: ajw@ysbl.york.ac.uk.
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986 N-myristoyltransferase from Leishmania donovaniIntroduction
The leishmaniases, caused by species of the
kinetoplastid parasite Leishmania, are a spectrum of
diseases associated with immune dysfunction that
give rise to N2 million new cases each year in 88
countries, with 367 million people at risk.1,2 Clinical
symptoms range from the disfiguring skin lesions of
cutaneous leishmaniasis to the often fatal visceral
leishmaniasis (VL). These are exacerbated in chil-
dren and immunocompromised patients, such as
those diagnosed as HIV positive. There is a limited
range of effective drugs in use including Pentostam,
amphotericin B (in its liposomal formulation,
AmBisome) and miltefosine, with a few others in
clinical trials.3 However, delivery regimens can be
complex, while miltefosine, the only oral VL drug
currently available, is teratogenic, limiting its
distribution in endemic populations. Moreover,
resistance is an increasing problem and there are
no effective vaccines currently available.4 There is
therefore a pressing need for new, preferably orally
administered drugs, particularly for VL.2 Previous
studies have identified myristoyl-CoA–protein N-
myristoyltransferase (NMT) as a suitable candidate
for drug development against protozoan parasitic
infections, including Leishmania major, the causative
agent of cutaneous leishmaniasis, as well as Plasmo-
dium falciparum and Trypanosoma brucei, causative
agents of human malaria and African sleeping
sickness, respectively.5–9
NMT is ubiquitous in eukaryotic cells in which it
catalyses the co-translational addition of the C14:0
fatty acid, myristate, via an amide bond, to the N-
terminal glycine residue of a subset of proteins. N-
Myristoylation plays a role in targeting proteins to
membrane locations, mediating protein–protein
interactions and stabilizing protein structures
(reviewed in Ref. 10). N-Myristoylation by NMT
proceeds via an ordered Bi–Bi reaction mechanism;
binding of myristoyl-CoA opens up a second pocket
for docking of the substrate protein.11,12 The
myristate group is then transferred to the N-
terminal glycine of the substrate in a nucleophilic
addition–elimination reaction, followed by stepwiseFig. 1. TheNMT gene codes for an essential enzyme in L. do
NMT locus and targeted single alleles containing replacement
represent NMT flanking regions used for gene targeting. 5′DH
reductase flanking regions. Arrows show positions of primers
labeled probe hybridized to membranes in (b) indicated by st
digests of parasite genomic DNA hybridized with 5′U probe, w
the following bands: 5.0 kb, HYG replacement at NMT locus;
locus. Upper panel: wild type (Wt), three single allele HYG r
generated from H4 +/ΔNMT::HYG parent clone by attempted
1–12). Lower panel: 12 clones generated from an H4 +/ΔNM
replacement with PAC (+/ΔNMT::HYG [pTEX NEO NMT]+ P
P1). (c) PCR analysis of the wild-type NMT locus (using prime
Nrev). Clones are as described in (b). (d) Groups of five BALB/
promastigotes (either wild-type parasites or one of the +/Δ
burdens in the spleen (left panel) and liver (right panel) were
methanol-fixed, Giemsa-stained tissue imprints, as previously
units (LDU), in which LDU represents the number of intracellu
Statistical analysis was performed by a paired Student's t-testrelease of first the free CoA and then the N-
myristoylated protein.11,13
NMTs have been well-characterised in Saccharo-
myces cerevisiae14 and human cells15 and are essential
for viability in pathogenic fungi.16 Comparative
sequence and biochemical analyses have demon-
strated high conservation of the myristoyl-CoA
binding sites in human and fungal NMTs but
divergent peptide-binding specificities.17 Given
these observations, peptide-based and peptidomi-
metic inhibitors have been developed that show
selectivity against the NMTs of fungal species as
compared to human NMT.18–20 As a consequence,
NMT has been the target of a number of antifungal
drug development programmes, with the focus on
selective inhibitors acting at the peptide-binding
pocket. In the preliminary stages of commercial
development of fungal NMT inhibitors, high selec-
tivity and specificity were achieved using two
different core scaffolds: benzothiazoles (Pfizer,
unpublished data) and benzofurans (Roche).21
Further progress was curtailed, however, due to
fungal species specificity of the best leads—new
antifungals of higher efficacy are required to be
broad spectrum, thereby reducing the necessity for
clinical diagnosis prior to treatment.
This rationale does not apply to parasitic diseases
such as leishmaniases, which are readily diagnosed
according to clinical, molecular and epidemiological
indicators. In L. major, the single-copy NMT gene is
constitutively expressed in all parasite stages,7 with
the 421-residue (48.5 kDa) monomeric protein
localizing to both cytoplasmic and membrane frac-
tions. Genome sequence analysis has identified 62
putative protein substrates for N-myristoylation in
this organism, of which ∼10 have been identified by
metabolic labeling.7,22 These include ADP-ribosyla-
tion factors (ARFs) and the infective stage-specific
hydrophilic acylated surface proteins (HASPs).
HASPB, which requires both N-myristoylation and
palmitoylation for transport to the parasite plasma
membrane,23 is a vaccine candidate for VL.24–26 The
L. major NMT has been genetically validated as
essential for the viability of insect-stage promasti-
gotes using targeted gene disruption techniques.7novani promastigotes. (a) Restriction maps of the wild-type
by either the HYG or PAC genes. 5′Flank and 3′flank boxes
FR and 3′DHFR boxes represent 5′ and 3′ dihydrofolate
used in PCR analysis of clones in (c). Position of the DIG-
ippled box. (b) Southern blot analysis of ScaI and BamHI
hich hybridizes to the 5′ flanking region. Arrows indicate
4.6 kb, PAC replacement at NMT locus; 3.7 kb, Wt NMT
eplacement (+/ΔNMT::HYG H1, H4, H16) and 11 clones
replacement with PAC (H4 +/ΔNMT::HYG+PAC clones
T::HYG parent clone overexpressing NMT by attempted
AC) and a single allele PAC replacement (+/ΔNMT::PAC,
rs Ufor and Nrev) and NMT ORF (using primers Nfor and
c mice were inoculated with 4×107 L. donovanimetacyclic
NMT::HYG clones [NMT SKO]) intravenously. Parasite
determined at 28 days post-infection by examination of
described 25. Data are presented as Leishman Donovan
lar amastigotes/1000 host cell nuclei × organ weight (mg).
.
987N-myristoyltransferase from Leishmania donovaniHere, we extend our studies on NMT to Leishmania
donovani (LdNMT), the principal causative agent of
the most serious form of leishmaniasis, and demon-
strate that theL. donovaniNMTgene is also likely to be
essential for viability in extracellular parasites. WithFig. 1 (legend onthe aim of exploiting LdNMT for drug discovery, we
have overproduced and purified the recombinant
protein in Escherichia coli and characterised its ligand-
binding properties and enzyme activity. In addition,
we have determined by molecular replacement theprevious page)
988 N-myristoyltransferase from Leishmania donovanihigh-resolution crystal structure of LdNMT in com-
plex with a non-hydrolysable myristoyl-CoA ana-
logue. The structure is discussed in relation to
sequence alignments and the structures of unli-
ganded, binary and ternary complexes of yeast and
fungal NMTs.Results and Discussion
The L. donovani NMT gene is essential for the
viability of insect-stage parasites
In L. major, targeted gene deletion methods were
used to demonstrate that the single–copy NMT gene
is essential for viability in promastigotes.7 Here, the
same approach has been taken to investigate
whether L. donovani NMT gene function is also an
essential requirement for propagation of this parasite
species. Linear constructs were generated, carrying
drug resistance marker genes [HYG (hygromycin
resistance gene) or PAC (puromycin resistance
gene)] flanked by dihydrofolate reductase sequences
conferring constitutive expression. These were tar-
geted to the NMT locus, using 5′ and 3′ intergenic
regions for homologous recombination (Fig. 1a).
Numerous heterozygous parasite clones (+/ΔNMT::
HYG or +/ΔNMT::PAC) containing an integrated
copy of one of the drug resistance genes were
obtained using this approach. Three +/ΔNMT::
HYG clones (H1, H4 and H16) were independently
transfected with pTEX NEO (neomycin) NMT7 to
generate clones overexpressing NMT from the pTEX
plasmid (H1, H4, H16 +/ΔNMT::HYG [pTEX NEO
NMT]). Attempts were then made to replace the
second NMT allele in all six clones by transfection
with the PAC linear targeting construct. Twelve
clones from each transfectionwere isolated (a total of
72 transgenic events) and further analysed by PCR,
DNA blotting and immunoblotting. The results of
these analyses are summarized in Table 1 and in Fig.
1, where examples of Southern blotting and PCR
analyses for clones derived from PAC targeting of
the +/ΔNMT::HYG parent clone H4 are shown.
Eleven out of 11 of these clones have retained a wild-
type NMT allele as shown by DNA blotting (Fig. 1b,
upper panel) and 12 of 12 as analysed by PCR
amplification (c, lower panel). By contrast, the
majority (10/12) of the PAC targeted NMT over-
expressing clones have lost the wild-type NMT
allele, with only clone 10 showing retention of thisTable 1. Summary of NMT gene analyses of transgenic paras
Clone properties Method of analysis +/
Expressed NMT Immunoblot
NMT ORF present PCR (primers Nfor+Nrev)
Maintained wild-type NMT locus PCR (primers Ufor+Nrev)
Maintained wild-type NMT locus DNA blot (NMT ORF probe)
HYG-replaced NMT locus DNA blot (5′U probe)
PAC-replaced NMT locus DNA blot (5′U probe)
a Multiple bands complicated analysis of H1 and H16 series.gene by Southern blotting (b, lower panel) and clones
10 and 12 by PCR amplification (c, upper panel).
Of the 72 clones analysed, none demonstrated a
complete absence of NMT coding sequence (see
Table 1 for the cumulative results from this
analysis). Many of the PAC-targeted +/ΔNMT::
HYG H4 clones showed evidence of both HYG and
PAC replacement at the NMT locus in addition to
the presence of a wild-type NMT gene elsewhere in
the genome (e.g., clones 1, 2, 5, 6 and 11; Fig. 1b,
upper panel). However, the majority of NMT
overexpressing clones had lost both wild-type
NMT alleles by gene replacement, while retaining
a copy of the NMT gene, presumably episomally.
Therefore, in these studies, we were unable to
generate a transgenic parasite line null for NMT
expression. Our overall interpretation of these data
is that L. donovani promastigotes require at least one
allele of the NMT gene for successful propagation in
culture. Expression of∼50% of the wild-type level of
LdNMT is also sufficient for parasite survival
following phagocytosis by macrophages in vivo, as
two +/ΔNMT::HYG clones were successfully pas-
saged through immunodeficient Rag−/−γ−/−mice.27
Similarly, intravenous inoculation of susceptible
BALB/c mice with wild-type L. donovani and one
of the +/ΔNMT::HYG clones (heterozygous for
NMT) revealed similar parasite burdens in the
liver and spleen at 28 days post-infection (Fig. 1d).
There was no significant difference between wild-
type and heterozygous infections in either tissue at
this time when insect-stage promastigotes have
differentiated into intracellular amastigotes. It is
not currently possible to selectively knock down
gene expression in intracellular Leishmania and test
at what point parasite viability is compromised with
decreasing expression and activity of LdNMT.Characterisation of NMT from L. donovani
We have cloned and sequenced the gene encoding
LdNMT from L. donovani strain LV9. Relative to the
coding sequence of the NMT gene of the closely
related Leishmania infantum strain JPCM5,28 there are
just two nucleotide differences (C to T transitions at
positions 258 and 492) neither resulting in an amino
acid substitution. There are only 11 amino acid
differences between LdNMT and the NMT of the L.
major Friedlin strain.
The L. donovani NMT was overproduced in E. coli
andpurified in goodyield (5mg l−1 of cell culture; seeites
ΔNMT::HYG+PAC +/ΔNMT::HYG [pTEX NEO NMT]+PAC
36/36 12/12 (H4 series)
36/36 36/36
33/36 2/36
34/35 1/12 (H4 series)a
28/35 36/36
18/35 36/36
Fig. 2. Protein mobility shifts on native electrophore-
sis. Altered mobility of LdNMT protein on non-denatur-
ing PAGE (7.5% polyacrylamide; run conditions, 90 V for
100 min) corresponds to complex formation with cofactor.
3 μg of protein (lane 1) was incubated with myristoyl-CoA
in 10-fold molar excess (lane 2) or 2-fold excess of ARF
peptide (lane 3). Low-mobility material is visible when
both cofactor and peptide are present (lane 4), which does
not appear when the non-hydrolysable cofactor NHM is
used (lane 5, protein+NHM; lane 6, +NHM+peptide).
989N-myristoyltransferase from Leishmania donovaniMaterials and Methods). The protein migrates as a
single band in nondenaturing gels following electro-
phoresis (Fig. 2, lane 1). For ligand binding and
activity assays, we used a peptide derivative repre-
senting a canonical myristoylation motif derived
from ARF and the non-hydrolysable myristoyl-CoA
analogue S-(2-oxo)pentadecyl-CoA (NHM) prepared
by an alternative synthetic route as described in
Materials andMethods and SupplementaryMaterial.
As shown in Fig. 2, themobility of the isolatedprotein
(lane 1) increases following incubation with either
myristoyl-CoA (lane 2) or NHM (lane 5) consistent
with the formation of binary complexes of LdNMT
and the fatty acyl-CoA species. Incubation with
peptide alone (lane 3) has no influence on mobility,
suggesting that LdNMT–peptide complexes are not
being formed, consistent with observations on
orthologous NMTs that there is compulsory order
in substrate binding and that the peptide binding site
is not accessible prior to fatty acyl-CoA binding.
Following preincubation with myristoyl-CoA and
addition of peptide substrate, there is additional
staining of material with low gel mobility (lane 4)
consistent with chemical transformation and the
formation of myristoylated peptides, which are not
formed when NHM is used as cofactor (lane 6).
The kinetics of the LdNMT-catalysed reactionwere
measured by a scintillation proximity assay (SPA)Table 2. Kinetic and inhibition analysis
Enzyme
Myristoyl-CoA
Vmax (cpm/min) Km
app (nM) Vmax
LdNMT 243.0±9.9 17.5±2.9 23
CaNMT29 713±23 2.8±0.4 8
ScNMT30 nd 1.4
Peptide used with each enzyme: LdNMT, GLYVSRLFNRLFQKK(Bio
determined.using [3H]myristoyl-CoA and the C-terminally bio-
tinylated ARF peptide GLYVSRLFNRLFQKK(Bio-
tin)-NH2.
5 The Km
app values of LdNMT for myristoyl-
CoA and the peptide are 17.5 ± 2.9 nM and 0.23 ±
0.12 μM, respectively (Table 2). These values cannot
be compared directly with those measured for
the NMTs of other species as the assay substrates
and conditions are different; nevertheless, the
numbers measured are of the expected order of
magnitude.29,30 NHM was shown to be a potent
inhibitor of the LdNMT-catalysed transfer of myr-
istate to the peptide. The IC50 value of 68.7±4.2 nM
(see SupplementaryMaterial) is in the range reported
for the NMTs from other species.17,31
Crystal structure solution and model
The structure of LdNMT was solved by molec-
ular replacement using the coordinate set 1NMT.
pdb32 as the search model. The refined coordinates
have good agreement with the X-ray data extend-
ing to 1.42 Å resolution, with Rcryst and Rfree
values of 14.6% and 19.1%, respectively (Table 3).
There is a single LdNMT molecule in the asym-
metric unit and the chain is well defined in the
electron density maps, with the exception of
residues 1–10 at the amino terminus and residues
83–85 and 334–339, which are not defined by the
maps and assumed to be disordered. The model
contains one molecule of S-(2-oxo)pentadecyl-CoA
and 378 water molecules.
In describing the structure, the secondary-struc-
ture nomenclature used by earlier workers will be
adopted32,33 in which helices are denoted with
uppercase letters and strands with lowercase letters
(Fig. 3). Secondary-structure elements additional to
those observed in the C. albicans NMT (CaNMT) are
denoted by one or more primes (′). The mean atomic
temperature factor for main-chain atoms is low at
15 Å2. The regions corresponding to A″, the C′C″
helical pair, the eC loop, the DEhF element, and
loops Ab and kl (which contain missing residues),
have residues with significantly higher average
main-chain temperature factors, suggesting that
these regions of the structure have independent
mobility. As described below, some of these regions
are of functional importance.
Overall structure
The core of the structure is a 12-strandedβ-sheet that
is strikingly twisted with strand order acdefngmlkjhPeptide
IC50 of non-hydrolysable
myristoyl-CoA (nM)(cpm/min) Km
app (μM)
0.4±26.6 0.23±0.12 68.7±4.2
31±25 0.36±0.04 nd
nd 0.9 nd
tin); CaNMT, GLTISKLFRR; ScNMT, GAAPSKIV-NH2. nd, not
Table 3. Data collection and refinement statistics
Data collection
Space group P212121
Unit cell dimensions
a, b, c (Å) 45.97, 90.13, 92.35
Resolution (Å) 40–1.42 (1.46–1.42)a
Rsym
b 0.097 (0.358)
〈I/σ(I)〉 10.8 (3.0)
Completeness (%) 98.1 (78.8)
Redundancy 7.4 (2.4)
Refinement
Resolution (Å) 40.0–1.42
No. reflections 68,150 (3,986)
Rcryst
c /Rfree
d (%) 14.6/19.1
No. atoms
Protein 3446
Ligand 64
Water 378
B-factors (Å2)
Protein 16.5
Ligand 14.3
Water 25.8
rmsde
Bond lengths (Å) 0.028
Bond angles (°) 2.18
Ramachandran plotf 91.5/8.2/0.3/0.0
a Values in parentheses are for the highest-resolution shell.
b Rsym=∑hkl∑i|Ii− 〈I〉|/∑hkl∑i〈I〉where Ii is the intensity of the
ith measurement of a reflection with indexes hkl and 〈I〉 is the
statistically weighted average reflection intensity.
c Rcryst=∑||Fo|−|Fc||/∑|Fo| where Fo and Fc are the
observed and calculated structure factor amplitudes, respectively.
d Rfree is the Rcryst calculated with 5% of the reflections chosen
at random and omitted from refinement.
e Root-mean-square deviation of bond lengths or bond angles
from ideal geometry.
f Percentage of residues in the most favoured/additionally
allowed/generously allowed/disallowed regions of the
Ramachandran plot.
990 N-myristoyltransferase from Leishmania donovani(Fig. 4a). The β-sheet forms an open barrel that
together with the three α-helices A, B and G
encloses a volume occupied by the C-terminal
segment of the polypeptide, so that the α-carbox-
ylate of the polypeptide chain is at the heart of the
molecule. The molecule has two lobes, each of
which has a multistranded β-sheet element at its
core flanked by two α-helices on one face and a
single α-helix on the other face (Fig. 4a). For the N-
terminal lobe, the sheet is made up of strands
acdefng with helices A and B packed onto one face
and helix C onto the other. For the C-terminal lobe,
the sheet comprises strands gmlkjh against one face
of which helices F and G are packed, with helix H
packed onto the other face.
There is pseudosymmetry within the molecule in
the form of tandem duplication such that the
topology of residues 56–134 and 161–221 matches
that of residues 264–404. The repeated segment has a
βαβαβββαββ topology (Fig. 4b) that largely defines
the two lobes with the exception of the final β-
strands, g and n, which cross over into the opposite
lobe. Residues 135–160 represent a prominent
insertion between strands d and e in the sequence
of the N-terminal lobe, and these residues form a
helix–loop–helix containing C′ and C″, whichprotrudes from the base of the molecule (Fig. 4a).
The corresponding segment of the C-terminal lobe
between strands k and l comprises just eight
residues most of which are disordered (Fig. 4b).
Outside the region of duplication, residues 221–
264, containing helices D and E and associated with
lobe 2, form the right flank of the molecule when
viewed as in Fig. 4a. The left flank comprises
residues 11 to 56 at the amino terminus of the
polypeptide, which form a long meandering seg-
ment that, with the exception of a short 310 helix (A′)
at the start of the chain and a six-residue α-helical
segment (A″), lacks secondary structure. These
largely exposed residues are often disordered in
NMT structures. Residues 404–421 at the carboxyl
terminus also lack secondary structure, though here
the last six residues are threaded through into the
centre of the molecule (Fig. 4a).
The structure of LdNMT is very similar to that of
the S. cerevisiae enzyme (41% sequence identity,
rmsΔ=1.4 Å for 373 equivalent Cα atoms). In NMT
from S. cerevisiae (ScNMT), the A′ 310 helix is present
but residues corresponding to the A″ α-helix in
LdNMT are in an extended conformation (Figs. 3
and 4c). The yeast NMT has an extra 26 residues at
the N-terminus relative to LdNMT, though these
appear to be disordered. The most striking distin-
guishing feature of LdNMT is the additional pair of
α-helices C′ and C″ (Fig. 4c). These structural
elements correspond to a prominent ∼20-residue
insertion at residue 140 in the sequence of the
Leishmania NMTs (Fig. 3). This helix pair is clearly
visible at the bottom of Fig. 4c, protruding from
the main body of the protein. Elsewhere, helix H
in LdNMT has three fewer turns than the cor-
responding helix in ScNMT (Fig. 4c) and the lH
segment is shorter, these differences accounting for
the gap in the alignment after residue 350 (Fig. 3).
The LdNMT also has a much shorter segment
connecting the final β-strand n with the C-terminus.
These differences in sequence/structure are on the
face of the β-sheet distal to the active site and
substrate-binding cleft and therefore unlikely to
have functional significance.
Substrate binding and loop movements
Detailed studies of NMTs have led to the proposal
of a structurally informed mechanism of action for
ScNMT,35 which may be extrapolated to LdNMT, in
which firstly the myristoyl-CoA and secondly the
target protein substrates bind to the enzyme. The
terminal carboxylate group of Leu421 acts as a base
to deprotonate the α-amino group of the terminal
glycine residue of the substrate, activating it for
nucleophilic attack on the carbonyl carbon of the
thioester linkage in myristoyl-CoA. It appears that a
conformational change following binding is re-
quired to bring the reacting groups into appropriate
juxtaposition for the chemistry to proceed. The
charge in the transition state of the reaction is
dissipated through the carbonyl oxygen, the oxya-
nion, with stabilizing interactions with the amide
Fig. 3. Sequence alignment of NMTs. Structure-based amino acid sequence alignment of NMT proteins of known
structure (Ld, L. donovani; Hs, human; Ca, C. albicans; Sc, S. cerevisiae). Strictly conserved residues are coloured red and
well-conserved residues are coloured yellow. The secondary-structure elements of LdNMT and ScNMT are shown above
and below the sequence alignment, respectively. This figure was generated using ESPript.34
991N-myristoyltransferase from Leishmania donovanigroups of Phe168 and Leu169. Following acyl group
transfer, there is ordered dissociation of first the
CoA and finally the myristoylated peptide.
The ordered binding of substrates is accounted for
by the displacement upon myristoyl-CoA binding of
the Ab loop, which partially occludes the binding
site for the N-terminal peptide of the substrate
protein.33,35 This loop, which serves as a lid that
opens and closes over the catalytic site, has variable
conformations among the different structures. It
partially occludes the myristoyl-CoA and peptide
binding sites in the structure of the uncomplexed
CaNMT, while in the binary and ternary complexes
of ScNMT the loop has swung upward to different
extents, opening up the active site. In this way, the
binding of myristoyl-CoA assists peptide binding by
ensuring the lid is open and the second substrate can
bind unhindered. The central residues of the lid in
LdNMT are missing from the model; moreover, the
flanking residues of the Ab loop have much higher
than average temperature factors, suggesting intrin-sic mobility of this segment of the structure. There
are some clashes between residues of this loop and
the GLYASKLA peptide from ScNMT following
superposition of the protein backbones (see below).
Taken together, it seems that the Ab loop is closed in
the uncomplexed enzyme and that following fatty
acyl-CoA binding the Ab loop adopts an ensemble
of structures that facilitate the binding of the N-
terminal peptide of the substrate protein.
Fatty acyl-CoA binding
LdNMT was co-crystallised with NHM, a non-
hydrolysable analogue of myristoyl-CoA with a
methylene group intervening between the sulfur
and the carbonyl carbon in what would otherwise be
the thioester linkage in myristoyl-CoA. As shown in
Fig. 5a, all 64 heavy atoms of the NHM are clearly
defined in the electron density maps with this ligand
residing in one side of a prominent groove running
across the molecule (Fig. 4c). The fatty acyl-CoA
992 N-myristoyltransferase from Leishmania donovanibinds to the N-terminal lobe in a site that is formed
by the eCf elements that encircle the cofactor, with
the A′ 310 helix and the Ab loop forming lateral
interactions (Figs. 4a and 5c). In its bound confor-
mation, 1070 Å2 or 88% of the cofactor's solvent-
accessible surface area of 1215 Å2 is buried by
interaction with the protein. The extensive interac-
tion surface is consistent with the low IC50 of NHM.
In the complex, NHM takes up a conformation
that has been described elsewhere33 as resembling aFig. 4 (legend oquestion mark, with the extended pantetheine and
fatty acyl species folding around the adenine base.
As a result, the majority of the interactions of the
adenine base and the ribose sugar are intramolecu-
lar, with interactions with the protein confined to
apolar contacts with Trp15 and Leu208 (Fig. 5c). In
contrast, the 3′ phosphate group forms a multitude
of interactions with the protein including ion pairing
with the side chains of His12 and Arg179 and
charge–dipole interactions with the main-chainn next page)
Fig. 5. Fatty acyl-CoA binding to LdNMT. (a) 2Fo−Fc electron density contoured at 3σ and displayed in the
neighbourhood of the NHM species in the refined LdNMT model. (b) Orthogonal views of the fatty acyl-CoA in the
LdNMT binary complex and ScNMT binary and ternary complexes. Carbon atoms are coloured according to structure:
LdNMT–NHM, cyan; ScNMT–myristoyl-CoA, green; ScNMT–NHM–GLYASKLA, coral. The fatty acyl-CoA species were
superposed by least-squares methods. (c) Stereo view of the NHM and neighbouring residues in LdNMT. The fatty acyl-
CoA is shown with thicker bonds relative to the protein and its carbon atoms are coloured in cyan rather than green. The
remaining atoms are coloured as follows: oxygen, red; nitrogen, blue, sulfur, yellow; phosphorus, magenta. The backbone
of the protein is indicated as a light blue ribbon. Polar interactions between the protein and the fatty acyl-CoA are
indicated by dashed lines. The figure was prepared with CCP4MG.36
993N-myristoyltransferase from Leishmania donovaniamides of residues 14 and 15 and water-mediated
interactions with the carbonyl and amide of residues
Ala11 and Ala13, respectively. The 5′ diphosphate is
stabilized by direct interactions with the main-chainFig. 4. The three-dimensional structure of LdNMT. (a) Ste
NHM, which is shown in cylinder format and coloured by ato
yellow; phosphorus, magenta. The protein chain is colour ram
at the C-terminus (magenta). The secondary-structure eleme
lowercase letters for β-strands. The ' and ” superscripts indica
structures to be described. (b) Topology diagram of LdNMT
helices represented as circles and β-strands as triangles. Lo
indicating the tandemly duplicated region. The italicised N and
C ″ appear as an insert coloured in orange in lobe 1 at a reg
representation of LdNMT. The molecule is shown in an orient
represents positive and negative electrostatic potential, respec
coloured by element as above except that carbon atoms are i
ScNMT. The structures of LdNMT–NHM and ScNMT–NHM–
SSM superpose routine in CCP4MG. The structures are display
ligands represented in cylinder format. The Ab loop from the
is shown in red.amides of Glu177 and Arg179 and water-mediated
interactions with the main-chain amide of Leu180
and the guanidine group of Arg179. There are polar
contacts between O9 of the pantetheine (O9p) andreo ribbon representation of LdNMT in its complex with
m type: carbon, cyan; oxygen, red; nitrogen, blue, sulfur,
ped from residue 11 at the N-terminus (red) to residue 421
nts are labelled with uppercase letters for α-helices and
te elements additional to those observed in the first NMT
with secondary-structure elements labelled and with α-
be 1 is shown above lobe 2 with the light blue shading
C indicate the chain termini. The additional helices C′ and
ion that is disordered in lobe II. (c) Electrostatic surface
ation similar to that in (a). Blue and red surface colouring
tively. The NHM ligand is shown in cylinder format and
n green. (d) Comparison of the structures of LdNMT and
GLYASKLA (PDB code 1IIC35) were superposed using the
ed as ribbons, LdNMT (blue) and ScNMT (green), with the
superposed ScNMT–myristoyl-CoA binary complex (1IIC)
994 N-myristoyltransferase from Leishmania donovanithe amide group of Val171 and between N4p and
the carbonyl group of Leu169. A further water-
mediated interaction occurs between O6p of pan-
tetheine and the exocyclic amino group of the
adenine base (Fig. 5c). Further apolar contacts of
the pantetheine are formed with Tyr80, Val81,
Val171, Ala181 and Arg176.
The carbonyl group of the pentadecyl moiety is
directed into the protein interior to form hydrogen
bonds with the main-chain amide groups of Phe168
and Leu169, these groups forming the oxyanion
hole. The aliphatic chain of the pentadecyl species is
in a largely extended conformation with slight
kinking of the chain at C5–C6 and C8–C9. It runs
into a deep hydrophobic pocket lined by residues
Trp15, Ile166, Leu169, Ile185, Val192, Trp198,
Gln199, Ala200, Tyr202, Leu208, and Tyr404 (Fig. 5).
The distal portion of the aliphatic chain runs
antiparallel to helix C and parallel to strand f with
the loop connecting these elements of secondary
structure forming the base of the pocket.
The conformation and interactions of the fatty
acyl-CoA in LdNMT are well conserved in the
structures of the yeast and fungal NMTs.35,37 As
shown in Fig. 5b, the NHM molecule from the
complex reported here is superimposed on the fatty
acyl-CoA entities from (i) the ScNMT complex with
NHM and the octapeptide GLYASKLA [Protein
Data Bank (PDB) entry 1IID] and (ii) the ScNMT
complex with myristoyl-CoA (PDB entry 1IIC). The
rmsΔ following least-squares minimization of the
positions of equivalent atoms is ∼0.6 Å in each case.
The closest overlap (0.3 Å) is at the active centre
where the carbonyl oxygen of the fatty acid is
directed into the oxyanion hole. The sulfur atom of
the NHM is displaced by just 1.1 Å from its location
in myristoyl-CoA, despite the presence of the
methylene group between the carbonyl group and
the sulfur in the former.Peptide binding site in LdNMT and HsNMT and
implications for drug design
Alignment of the sequence of LdNMT and human
NMT (HsNMT) reveals 42% residue identity over
their 421 and 495 residues, respectively. We are
interested here in the sequence differences between
the L. donovani and human enzymes and their
structural consequences for the discovery of selec-
tive inhibitors of LdNMT. The myristoyl-CoA
binding site in NMTs is very well conserved
among species, and the interactions of fatty acyl-
CoA with the enzyme are conserved in the
structures that have been determined. Attention
has therefore been directed toward the development
of inhibitors that bind in the peptide binding site.
There is conservation of sequence in the peptide
binding groove; nevertheless, selective inhibitors of
yeast and fungal NMTs have been discovered that
bind in this location, exploiting residue differences
at a handful of positions and often subtle differences
in structure.33,37The consensus sequence for N-myristoylation is
loose and restrictive only over four of the six N-
terminal residues.38,39 The N-terminal residue must
be glycine, while at the second position, charged
residues, proline and large hydrophobic residues are
not allowed. At positions three and four, most, if not
all, residues are allowed. Small but uncharged
residues are allowed at position five (Ala, Ser, Thr,
Cys, Asn and Gly) where serine is favoured, while
the sole restriction at position six is that proline is
not present (PROSITE pattern PS00008).40
To illuminate the character of the peptide
binding surface in LdNMT, we superposed the
binary complex of LdNMT with NHM onto the
ternary complex of ScNMT with NHM and the
octapeptide GLYASKLA (Fig. 4d). The octapeptide
lies across the β-sheet in the C-terminal domain of
the protein forming interactions with residues of
strands k, l, m and g, loops DE, In, and Ab as well
as with the C-terminal carboxylate and the fatty
acyl-CoA (Fig. 4d). The residues that are predicted
to surround this peptide in LdNMT are Tyr80, Val
81, Glu82, Phe88, Phe90, Tyr92, Asn167, Thr203,
Tyr217, His219, Phe232, Tyr326, Ile328, Ser330,
Leu341, Ala343, Tyr345, Val374, Asn376, Asp396,
Leu399, Met420 and Leu421 (Fig. 6). These residues
are conserved in LdNMT and HsNMT with the
exception of Ile328 (Leu), Met420 (Leu) and Leu421
(Gln) (Figs. 3 and 6).
A high-resolution structure of HsNMT in complex
with myristoyl-CoA has recently been released to
the PDB (PDB code 3IU1; unpublished data) by the
Structural Genomics Consortium (SGC). This struc-
ture and that of the binary complex of LdNMT can
be superposed to give an rmsΔ of 1.25 Å in the
positions of 369 equivalent Cα atoms. In relation to
substrate binding, the superposition reveals differ-
ences in the loops forming the upper surface of the
peptide binding site as viewed in Fig. 4, including
the ordering of the Ab and kl loops, which are
disordered in LdNMT. In contrast, there is disorder
in the central residues of the DE loop in HsNMT.
This loop is five residues longer in LdNMT (Fig. 3)
and it is ordered in the parasite enzyme. The
trajectory of the DE loop is altered so that it more
closely surrounds the peptide binding pocket in
HsNMT. It is predicted, based on comparison with
GLYASKLA bound to ScNMT, that residue His313
in HsNMT would interact with the peptide sub-
strate. This residue corresponds to Gly234 in
LdNMT, and this and further residue differences
in this loop at positions 236 to 238 in LdNMT may
present an opportunity for selective inhibitor elab-
oration (Figs. 3 and 6).
The structures of ternary complexes of HsNMT in
complex with myristoyl-CoA and three different
polycyclic inhibitor molecules have also recently
been released by the SGC (PDB codes 3IU2, 3JTK
and 3IWE; unpublished data). The inhibitors reside
in the extended groove distal to the myristoyl-CoA
binding site and overlapping with the peptide
binding site in ScNMT. The inhibitors partially fill
the volume occupied by the N-terminal and central
Fig. 6. Conservation of residues in the peptide binding pocket of LdNMT andHsNMT. Stereo view of the GLYASKLA
peptide from the ternary ScNMT complex (1iid.pdb) displayed in the context of the LdNMT peptide binding groove. The
LdNMT structure (displayed as a cyan ribbon) was superposed onto that of the yeast NMT using the SSM routine in
CCP4MG and is displayed together with the GLYASKLA peptide (thick light green cylinders) from ScNMT. The peptide
runs N to C, bottom to top in the figure. Side chains of LdNMT residues in the vicinity of the peptide are displayed in thin
cylinder format and coloured in coral for residues that are conserved in HsNMT and in ball-and-stick format with atoms
coloured by element for positions where the LdNMT and HsNMT sequences diverge. Selected residues are labelled in
black at conserved positions and red at divergent positions. The NHM species has been omitted for clarity.
995N-myristoyltransferase from Leishmania donovaniresidues of the peptide35 and, in two cases, extend
into the enlarged pocket for peptide side chain 4.
The inhibitors also explore additional volume not
occupied by the peptide, which is of significance for
inhibitor discovery. In relation to the NMTs of other
kinetoplastids, the residues predicted to form the
peptide binding groove in L. donovani NMT (Fig. 6)
are fully conserved in the NMTs from the patho-
genic Leishmania species L. major, L. infantum and L.
braziliensis and different in the NMTs of T. brucei and
T. cruzi at two (Ile328 replaced by Leu and Leu421
by Val) and four (Tyr326 replaced by Phe, Ile328 by
Leu, Gly234 by Leu, and Gln238 by His) positions,
respectively.
Concluding remarks
The studies described here show that NMT is
likely to be an essential gene in the L. donovani life
cycle, thus genetically validating LdNMT as a
suitable target for drug discovery for VL. The
overproduction and purification of recombinant
LdNMT, and the demonstration of peptide myr-
istoylation activity in an SPA that is adaptable to
large-scale parallel application, pave the way for
high-throughput inhibitor screening. The determi-
nation of the crystal structure of the LdNMT–NHM
complex establishes a foundation both for the
structural analysis of inhibitor complexes and for
structure-assisted drug discovery. The next step is to
carry out inhibitor screening. Industrial antifungal
drug discovery programmes targeting NMTs led tothe identification of highly potent inhibitors with
selective action. However, for these programmes,
directed at broad-spectrum inhibitors against a
range of fungal pathogens, species selectivity was
undesirable. These experiences augur well for the
search for parasite-directed NMT inhibitors where
broad-spectrum activity is not a requirement.
Materials and Methods
Parasite culture, generation of transgenic lines and
infectivity analysis
Promastigotes of L. donovani MHOM/ET/67/L28 (LV9
strain) were maintained at 26 °C in modified RPMI 1640
medium (Sigma-Aldrich) supplemented with 20% fetal
calf serum (Invitrogen). For targeted deletion of the single-
copy L. donovani NMT gene, plasmids were generated
containing either a hygromycin resistance gene (HYG) or a
puromycin resistance gene (PAC) flanked with DNA
sequences immediately upstream and downstream of
the NMT open reading frame (ORF). These constructs,
designated LdonNMTKO-HYG and LdonNMTKO-PAC,
respectively, were created by replacing the corresponding
L. major sequences in pNMT-HYG.7 To generate
LdonNMTKO-HYG, primers were designed from the L.
infantum NMT flanking sequences (LinJ32_20070420_V3).
A 748 bp fragment immediately upstream of the NMT
ORF was amplified using a proofreading DNA polymer-
ase (KOD, Merck, UK) from L. donovani genomic DNA
with primers LinfNMT5′Uf (5′-actaagcttCACACACTGT-
GAGCCTTGG-3′) and LinfNMT5′Ur (5′-atagtcgac-
CAGTCGCCCCTACTTGAGTC-3′). L. infantum sequence
996 N-myristoyltransferase from Leishmania donovaniis shown in upper case. The amplified product was
digested with HindIII–SalI and used to replace the
corresponding L. major sequence in pNMT-HYG. A 952 -
bp fragment immediately downstream of the L. donovani
NMT ORF was similarly amplified using primers
LinfNMT3 ′Uf (5 ′ -atacccgggTTTCACCCTCCTT-
CACGTTC-3′) and LinfNMT3′Ur (5′-cctagatctCTGCC-
GAGAAAAGAGGTCAT-3′). After digestion with SmaI–
BglII, this was used to replace the 3′-flanking L. major
sequence at the corresponding site. To generate
LdonNMTKO-PAC, PAC was released from plasmid
pNMT-PAC7 and used to replace HYG at the SpeI–
BamHI site in LdonNMTKO-HYG. Linear targeting
regions (5 μg; produced by digesting LdonNMTKO-HYG
and LdonNMTKO-PAC with HindIII–BglII) were purified
and used sequentially to transfect 2×107 mid-log phase L.
donovani promastigotes by nucleofection using a Human T
Cell Nucleofector kit (Amaxa). Plasmid pTEXNMT Neo7
was also transfected into single allele HYG replacement
clones to create NMT-overexpressing parasites. Individual
clones of all lines were selected and characterised as
described.7 Genomic DNAwas analysed by PCR using the
following primers: Ufor, 5′-CATTCCGAGAAGGGAGG-
GAG-3′; Nfor, 5′-CTACGTCGAGGACGACGACA-3′;
Nrev, 5′-GTGTCTCGAGCTACAACATCACCAAGG-
CAACCTGA-3′. Southern blotting was carried out with
digoxigenin (DIG)-labeled probes and hybridization
reagents (Roche) as per the manufacturer's protocols.
DIG-5′U probe, 780 bp, synthesized using primers
LinfNMT5′Uf and LinfNMT5′Ur; DIG-NMT ORF probe,
∼1 kb, synthesized using primers Nfor and Nrev.
Groups of five BALB/c mice were infected with 4×107
L. donovani metacyclic promastigotes (either wild type or
one of the +/ΔNMT::HYG clones) intravenously via the
tail vein in 200 μl of RPMI 1640 (GIBCO, Paisley, UK) and
parasite burdens in liver and spleen were measured at
28 days post-infection, as previously described.25 Statisti-
cal analyses were performed by paired Student’s t-test.
Experiments were approved by the University of York
animal procedures and ethics committee and performed
under UK Home Office license.
Cloning, expression and purification of L. donovani
NMT
The NMT ORF was amplified from L. donovani genomic
DNA by PCR using primers based on the sequence ofNMT
from the closely related L. infantum strain JPCM5.28
Primers NMT-Xho (5′-GTGTggatccCGCAATCCATC-
GAACTCTGACGCT-3′) and NRev (see above) contain
BamHI and XhoI recognition sites, respectively, for cloning
of the amplified fragment into pGEX-6P (GEHealthcare) in
order to express the enzyme as a C-terminal fusion protein
with glutathione S-transferase. One clone with silent
mutations in codons Ile360 (ATT→ATC) and Pro413
(CCC→CCT) was used to amplify a fragment using
primers NMT-Xho and NMT-Nde (5′-GTTGTTGTTca-
tatgTCTCGCAATCCATCGAACTCTGAC-3′). This was
cloned into a modified pET28 vector to incorporate an N-
terminal hexahistidine tag. Both fusion proteins can be
cleaved with HRV 3C protease to release NMT.
The recombinant plasmid encoding a His-tagged
LdNMT was introduced into E. coli BL21(DE3) pRareS,
and expression was achieved by growth in an autoinduc-
tion medium41 with overnight growth at 18 °C. Cell
lysates were prepared by sonication in a buffer containing
protease inhibitors, bovine pancreatic DNaseI, and a
nonionic surfactant, Triton X-100 [0.1% (v/v)]. The
unclarified cell lysate was loaded directly onto animmobilised metal-affinity chromatography column (GE
Healthcare 1 ml HisTrap FF Crude). Fractions containing
LdNMT were identified, pooled and diluted 10-fold in
50 mM Tris–HCl (pH 8.5) before loading onto an anion-
exchange column (GE Healthcare 1 ml HiTrap Q HP) and
elution by a linear gradient of 50 mM–0.5 M NaCl in
buffer. Gel filtration on a Superdex 75 16/60 column (GE
Healthcare) in 20 mM Tris buffer (pH 8.5), 200 mM NaCl
and 2 mM DTT was used as a final purification step.
Protein was concentrated and stored at −20 °C in 25%
glycerol, 20 mM Tris–HCl (pH 7.5), 100 mM NaCl, 2 mM
DTT, 2 mM EGTA [ethylene glycol bis(β-aminoethyl
ether) N,N′-tetraacetic acid] and 2 mM EDTA (ethylene-
diaminetetraacetic acid). The protein yield was typically
5 mg per litre of cells. For crystallography, the N-terminal
tag was removed by incubation with a His-tagged HRV
3C protease (Novagen, 10 U per milligram His6-NMT
protein) for 16 h at room temperature, before removal of
any uncut protein (approximately 50% of total), cleaved
His-tag and protease by passage through a 1 ml HisTrap
HP Ni-column followed by buffer exchange.
Protein crystallisation and structure solution
LdNMT [8 mg/ml in 50 mM Tris (pH 8.0), 50 mMNaCl]
was crystallised by the vapour-diffusion method. Hang-
ing drops consisting of 1.25 μl protein and 1.25 μl of
reservoir solution containing 0.6 M lithium chloride, 20%
(w/v) PEG (polyethylene glycol) 6000, 4% (v/v) 1,4-
butanediol in 0.5 M sodium citrate buffer (pH 4.0) were
equilibrated against 0.8 ml of reservoir solution at 20 °C.
These conditions were derived from the JCSG+Suite
(Qiagen) condition C2. Crystals appeared after a week
with dimensions of less than 100 μm. Preliminary X-ray
analysis established that the crystals belong to the
orthorhombic space group P212121 with cell dimensions
a= 46.0 Å, b= 90.1 Å, c= 92.4 Å. Assuming one molecule
per asymmetric unit, the Matthews coefficient is 1.96 Å3/
Da and the solvent content is 37%. Crystals were flash-
vitrified directly in liquid nitrogen before storage.
Data were collected on synchrotron beamline ID23.1
(λ= 0.976 Å) at the European Synchrotron Radiation
Facility (ESRF) (Grenoble) and processed using DENZO
and SCALEPACK.42 Data collection and refinement
statistics are summarised in Table 3. All data were
used in molecular replacement calculations in the
program MOLREP43 using the CaNMT coordinate set
(PDB code 1NMT,32 43% sequence identity) as the search
model after making mutations to match the LdNMT
sequence in the program CHAINSAW.44 Automated
model building was carried out using flex-wARP,45
which found 384 residues with a sequence coverage of
90%. During this process the Rcryst dropped from 0.30
(Rfree 0.32) to 0.21 (0.26). The model was refined by
iterative cycles of REFMAC546 using anisotropic tem-
perature factors and TLS parameters, interspersed with
manual modeling and adjustments carried out in
COOT.47 Refinement was concluded with an Rcryst of
14.6% (Rfree 19.1%) for data in the range 40–1.42 Å. The
final model contains 64 cofactor NHM atoms, 378 water
molecules and 402 protein residues, of which 91.5% lie
in the most favoured, 8.2% in the additionally allowed
and a single residue (Leu381) in a generously allowed
region of the Ramachandran plot.
Ligand binding and acyl transferase activity assay
Enzyme activity was measured by an SPA.5 The peptide
substrate GLYVSRLFNRLFQKK(Biotin)-NH2 was stored
997N-myristoyltransferase from Leishmania donovanias a 20 mM stock solution in dimethyl sulfoxide. Both [9,10
(n)-3H]myristoyl-CoA [3.51 μM at 57 Ci/mmol in 0.01 M
sodium acetate (pH 5.6)/ethanol (1:1) solution] and
streptavidin PVT beads were purchased from GE Health-
care. A typical assay (100 μl scale) contained variable
amounts of an inhibitor, 29.0 ng of purified LdNMT,
62.5 nM [3H]myristoyl-CoA (8 Ci/mmol) and 250 nM of
peptide substrate in 4% dimethyl sulfoxide buffer 1
[30 mM Tris–HCl (pH 7.4), 0.5 mM EDTA, 0.5 mM
EGTA, 2.5 mM DTT, 0.1% Triton X-100]. Incubation for
30 min at 37 °C was followed by the addition of 100 μl of
bead-stop solution [1 mg/ml in 0.2 M phosphoric acid
(pH 4.0), 0.75 mM MgCl2, 0.05% (w/v) bovine serum
albumin, 0.01% (w/v) NaN3] to terminate the reaction.
Overnight settling of the beads resulted in an accurate
reading with high signal-to-noise ratio. The instrument
used for counting was a Plate Chameleon multilabel
reader (Hidex Oy, Finland).
The inhibitory activity of the non-hydrolysable myr-
istoyl-CoA analogue (NHM) was measured at concentra-
tions between 10 μM and 0.01 nM. The readout of [3H]-
myristoylated peptide in the reaction lacking inhibitor
was defined as 100% activity, and that from the reaction
lacking enzyme was defined as 0%. The effects of the
inhibitor at each concentration were calculated as a
percentage of the control and the 50% inhibitory concen-
tration (IC50) of the inhibitor was calculated by nonlinear
regression analysis using Grafit 6.0.3 version (Erithacus
Software Limited, UK). Assays were performed in
triplicate.
The Km for myristoyl-CoA was evaluated by varying
the concentration of [3H]myristoyl-CoA between 500 and
0.23 nM, at a fixed 500 nM concentration of the assay
peptide. The Km with respect to peptide was evaluated by
varying its concentration over the range 10–0.04 μM, at a
fixed concentration of [3H]myristoyl-CoA of 62.5 nM. The
amount of beads added in the stop solution was
proportional to the amount of peptide used in the
assay. The reactions were quenched after 1, 3 and
5 min, and the initial reaction velocities were derived.
Data were analyzed by nonlinear regression (Michaelis–
Menten) and linear regression of a double-reciprocal plot
(Lineweaver–Burk) using Grafit 6.0.3 version (Erithacus
Software Limited, UK). Assays were performed in
duplicate.
Synthesis of S-(2-oxo)pentadecyl-CoA
The non-hydrolysable myristoyl-CoA analogue
(NHM) S-(2-oxo)pentadecyl-CoA was synthesised from
commercially available pentadecan-2-one. In brief, the
starting ketone was reacted with Hünig's base (diiso-
propylethylamine) and trimethylsilyl trifluoromethane-
sulfonate to form the terminal silyl enol ether, which
was immediately reacted with N-bromosuccinimide to
yield 1-bromopentadecan-2-one in 67% yield after
purification by flash silica column chromatography.
Direct displacement of the bromine with CoASH
yielded, after purification by reversed-phase HPLC, S-
(2-oxo)pentadecyl-CoA in 31% unoptimised yield. A full
description of the synthesis is given in the Supplementary
Material.
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